Catapult Therapeutics to attend Bio-Europe Spring 2019 in Vienna on March 25–27 for partnering discussions

Catapult Therapeutics will be attending BIO-Europe Spring 2019 in Vienna on March 25–27 to meet and continue discussions with potential pharmaceutical partners for the development and licensing of CAP-100, the company’s a first-in-class humanized anti-CCR7 antibody.

CAP-100 is a novel treatment for CCR7-positive hematological malignancies, such as chronic lymphocytic leukemia and non-Hodgkin lymphomas. The chemokine receptor CCR7 is over-expressed in many cancers, and high CCR7 expression is associated with poor prognosis and short survival in hematological and solid malignancies.

CAP-100 will be the first therapy to target CCR7. CAP-100 has unique mechanisms of action: it inhibits migration of tumor cells to the lymph node, and simultaneously kills tumor cells in the peripheral blood.

CAP-100 is currently in preclinical development and will be IND ready by the end of 2019. Catapult Therapeutics plans to test the antibody on chronic lymphocytic leukemia to provide the first clinical proof of its effectiveness.

To schedule a meeting, please do so via BIO-Europe’s online partnering platform at:, or contact

Dr Wim Mol, CEO, Catapult Therapeutics B.V.